Hepatitis C Virus (HCV) is a global health problem with over 170 million people with a chronic HCV infection. 1 Depending on the genetic differences, HCV is grouped into six genotypes with around half of the Swedish patients being infected with genotype 1. In Sweden the prevalence of chronic HCV is 0.36%, which corresponds to approximately 35 000 patients. 2 The standard of care was, until 2011, 48 weeks of weekly injections of pegylated interferon (pegIFN) and daily ribavirin (RBV) tablets. The treatment cured around half of the genotype 1 patients, but was associated with severe side effects. The objectives of this project were:
•to calculate the cost per cure per HCV treatment available in genotype 1.
•to estimate the budget impact of HCV treatments for the regional/national budget holder to allow planning for budget and resources.
•to evaluate the financial (economic) impact of new treatments on the burden of disease including long-term implications.
Long-term impact of treatment
The design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the study design, data/input extraction, modelling review, interpretation of results, review and approval of the publication. The authors determined the final content. No payments were made to the authors for writing this publication. K. Neovius is a consultant for AbbVie AB. J. Söderholm and K. Büsch are employees of AbbVie Sweden and may hold stocks or stock options in AbbVie. K. Büsch is also a registered PhD-student at Karolinska Institutet. An interactive tool to estimate the cost per cured as well as the total budget impact for different treatments was developed using data from the literature. Cost per cure was calculated as total treatment costs, divided by the number of cured patients within naïve, experienced and cirrhotic patient groups (based on cost and efficacy inputs from publish sources and clinical trial data). To evaluate the long-term consequences of different treatments, a Markov model with transition probabilities from the published model in the field by Lidgren et al (Figure 1 ) was used. 4 The model can be easily be adapted to reflect different patient cohorts or regional differences. A model flexible for regional and national Swedish cohorts of hepatitis C patients was developed, which can be adapted to different settings.
The new hepatitis C treatments could improve virologic outcomes among patients. In the long-term, cost-savings from reduced burden of disease among these patients are also to be expected. However, in the short term these treatments will require twice the budget size compared with the old less effective HCV treatments.
In the base case, taking only treatment costs into account, the cost per cure varied from 387 120 SEK (for Viekirax+Exviera) to 645 095 SEK (for Olysio+Sovaldi) in genotype 1 naive patients for 12 week treatment length (Figure 3) .
The cost per cure for 12 week Incivo + 24 weeks pegIFN/RBV in naive patients was slightly lower. However, this estimate does not take the higher rate of adverse events and associated costs into account. Financial long-term implications estimated for the same cohort of 100 patients are shown in Table 5 below. Investing in newer, more effective treatments can result in an overall decreased budget impact.
Transitional probability for fibrosis progression (i.e., transitions from F0-F1, F1-F2, F2-F3, and F3-F4) were taken from Thein et al. 5 For disease progression from compensated cirrhosis to more advanced disease states (i.e., decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC), liver transplant), data are sourced from Lidgren et al (Table 1) . 4 For patients with chronic hepatitis C, the same mortality risk as the general population was assumed. Only those patients, who progress to DCC, HCC or transplantation, were assumed to have an excess risk per Table 2 .
The treatment length was based on the Summary of Product Characteristics (SmPC) for each product and Swedish medical treatment guidelines. 3 The efficacy data was taken from the SmPCs Table 3 ). [6] [7] [8] [9] [10] [11] [12] [13] Treatment costs were calculated based on SmPC dosing 6-12 , treatment length from Swedish medical treatment guidelines and public prices (www.apoteket.se; August 2015; Figure 2 ).
Annual health care costs for each health status were taken from Orrskog et al. 13 These costs were then recalculated from Euros into Swedish kronor (SEK) with an exchange rate of 9.45 SEK / EUR, and inflated to 2014 prices using the consumer price index (www.scb.se; Table 4 ).
Indirect costs were estimated using the human capital approach and were based on Swedish salary adjusted for part-time, unemployment and employer contributions (www.scb.se; www.skatteverket.se).
BACKGROUND RESULTS
In cirrhotic patients the cost per cure for 12 week treatment per Swedish medical treatment guidelines varies between 410 314 SEK (for Viekirax+Exviera) and 692 979 SEK (for Incivo+48 weeks pegIFN/RBV; Figure 4) .
Therefore, the long-term implications and life-time costs were estimated (taking other direct costs and indirect costs into account). In the long-term, the superior effectiveness of the new treatments will translate into decreases in cases of decompensated cirrhosis, hepatocellular carcinoma and liver transplants of 88% among these patients (Figure 6 ).
County council specific assessments can be made based on regional data to evaluate the impact in the respective region. The model proved to be robust in general to alterations of variable values in oneway sensitivity analysis. The most important variables for the calculations were the costs / length of the HCV-treatments, and the effects of these treatments. An investment in new treatment options will result in fewer cases of decompensated cirrhosis, hepatocellular carcinoma, and liver transplantation. This will be beneficial with reduced costs for the health care system and the society, as well less suffering for the patients.
In a county council with a budget of 54 million SEK and a patient split of 70% naïve, 20% experienced and 10% cirrhotic patients, more Genotype 1 patients could be treated and cured with Viekirax+Exviera than with any of the other treatment regimes (Figure 5) . With all new interferon-free treatments, fewer patients (<5) would not be cured compared to Invico+pegIFN/RBV (>40).
IFN=interferon; peg=pegylated; RBV=ribavirin; SVR=sustained virologic rate. * Costs for RBV were not included, as they were negligible and were only applicable in patients with genotype 1a infection. **All SVRs from Olysio/Daklinza + Sovaldi treatments were only available from phase 2 trials. Few patients with genotype 1a and cirrhosis were treated with 24 weeks of Viekirax + Exviera, with a corresponding SVR of 97%. 
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Patients who are not being cured are still at risk of developing complications (e.g. DCC, HCC), which can lead to high costs to the health care system and society. 
